



## **Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day**

March 27, 2023

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- [Beam Therapeutics Inc.](https://www.beamtx.com) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Guggenheim 2023 Genomic Medicines and Rare Disease Day on Monday, April 3, 2023 at 10:10 a.m. ET in NYC.

A live webcast will be available in the investor section of the company's website at [www.beamtx.com](https://www.beamtx.com), and will be archived for 60 days following the presentation.

### **About Beam Therapeutics**

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

### **Contacts:**

#### Investors:

Chelcie Lister

THRUST Strategic Communications

[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)

#### Media:

Dan Budwick

1AB

[dan@1abmedia.com](mailto:dan@1abmedia.com)